INDUSTRY NEWS

01.002 RWE TNT May 2022 E 20-05-22

Clinical outcomes of anti-obesity medications (AOMs) assessed in real-world practice

  • The review showed a weight reduction in specific populations such as, patients who had regained weight or experienced inadequate weight loss after bariatric surgery, and specific patient subgroups such as T2DM
  • Weight loss was often accompanied by positive changes in other cardiometabolic risk factors, when measured
  • Although AOMs were well tolerated in real-world studies with mostly mild to moderate AEs, a general pattern of poor compliance was apparent with all treatments
  • The review identified large gaps in the evidence base for AOMs in treating patients with obesity or overweight in real-world practice, including few comparative effectiveness studies and a narrow range of reported outcomes
  • Strengthening the approach to RWE generation in obesity will help build a more accurate picture of the value of AOMs in routine clinical practice, especially as newer agents promising greater efficacy are on the horizon
Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.

About DISTILL

DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

Ref: RWEMAY2022TNTE